%0 Journal Article %A Susan J. Bartlett %A Vivian P. Bykerk %A Roxanne Cooksey %A Ernest H. Choy %A Rieke Alten %A Robin Christensen %A Daniel E. Furst %A Francis Guillemin %A Serena Halls %A Sarah Hewlett %A Amye L. Leong %A Anne Lyddiatt %A Lyn March %A Pamela Montie %A Ana Maria Orbai %A Christoph Pohl %A Marieke Scholte Voshaar %A Thasia G. Woodworth %A Clifton O. Bingham 3rd %T Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary %D 2015 %R 10.3899/jrheum.141169 %J The Journal of Rheumatology %P 2185-2189 %V 42 %N 11 %X Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided.Methods. Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations.Results. Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged ≥ 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues.Conclusion. These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement. %U https://www.jrheum.org/content/jrheum/42/11/2185.full.pdf